Nieng Yan, a Chinese structural biologist and dean of the Shenzhen Medical Academy of Research and Translation, stated in a December 18 Weibo post that family is one of the main reasons behind her recent return to China, also discussing her parents' experience of being infected by COVID-19.
Jackson He, the senior vice president of Baidu and general manager of the firm's Mobile Ecological Business Group, on December 17 participated in the China pavilion for the second phase of the COP15 to share the firm's innovative exploration and achievements in ecological protection.
On the evening of December 13, Fosun Pharma, the exclusive commercial partner of Chinese COVID-19 oral drug Azvudine, confirmed that the pills can soon be prescribed through online medical platforms.
On December 13, the online COVID-19 Clinic of a Chinese internet hospital under 111, Inc., a domestic digital healthcare platform, began to pre-sell Paxlovid (nirmatrelvir tablets; ritonavir tablets), an oral antiviral drug for COVID-19. However, shortly after the news was reported, the drug was quickly removed from online platforms.
On December 10, Nieng Yan, a well-known Chinese structural biologist who recently resigned as a professor at Princeton University and returned to China, was appointed as the dean of Shenzhen Medical Academy of Research and Translation.
Nieng Yan, a well-known Chinese structural biologist, responded on Twitter-like Weibo on November 11 to topics such as her resignation from Princeton University, her return to China, and her core research direction being replaced by AI.
Nieng Yan, a well-known Chinese structural biologist, announced on November 1 that she would resign as a tenured faculty member at Princeton University and return to China. On November 2, Yan responded to the matter.
On the morning of November 1, Chinese structural biologist Nieng Yan, the Shirley M. Tilghman Professor of Molecular Biology at Princeton University, announced that she will resign from the university and set up the Shenzhen Medical Academy of Research and Translation in China.
Demeter Bio-Tech (Zhuhai) Co., Ltd., a microalgae product synthesis enterprise, has recently completed a pre-A round of financing totaling nearly 100 million yuan ($14.50 million).
Contract development and manufacturing organization (CDMO) IntellectiveBio announced its completion of round-C financing on August 5, with a total amount exceeding 500 million yuan ($74.1 million). This round was led by Gaorong Capital and CTS Capital.
Sironax, an emerging biotechnology company, announced on August 2 its completion of round-B financing, bringing the firm's total fundraising to more than $300 million.
Biotechnology startup MobiDrop completed an A+ round of financing worth nearly 100 million yuan ($14.8 million). The funding was led by LYFE Capital, followed by existing shareholder Source Code Capital and local government guidance entity Yunxiang Fund.
BioHandler, a Shanghai-based life sciences tech startup, announced on July 18 that it has completed its first round of financing totaling nearly 100 million yuan ($14.8 million). This financing was jointly led by Proxima Ventures and GL Ventures.
Beijing-based tech giant and TikTok owner ByteDance has recently ventured into the life sciences sector. Last October, the firm invested in biotech startup Shuimu BioSciences.
Shanghai-based tech firm Biotree has completed round-A financing, garnering nearly 100 million yuan ($14.79 million). The round featured exclusive investment from Qiming Venture Partners.
Chinese startup Rocket Pi has secured tens of millions of yuan in pre-A round financing, led by Huagai Capital and followed by several famous angel investors in the hard technology field.
Mojia Biotech has recently completed round-B financing worth over $80 million, led by Temasek and followed by Santo Investment and LYZZ Capital.
Biofabrication firm MicroCyto has announced its completion of angel investment totaling nearly 100 million yuan ($15.0 million). The leading investor was Matrix Partners.
Xbiome Biotech Co., Ltd., an AI-based microbiome drug development company in Shenzhen, China, announced the completion of a B-round of financing totaling nearly $100 million.
In last week’s China VC news, local coffee brand Nowwa Coffee bags $31.51 million in its Series B and B+ Rounds, supermarket chain T11 rakes in $100 million in its latest financing round led by Alibaba and more.